Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Equity Average (2021 - 2025)

ARS Pharmaceuticals' Equity Average history spans 5 years, with the latest figure at $131.0 million for Q4 2025.

  • For Q4 2025, Equity Average fell 42.79% year-over-year to $131.0 million; the TTM value through Dec 2025 reached $131.0 million, down 42.79%, while the annual FY2025 figure was $185.5 million, 23.9% down from the prior year.
  • Equity Average for Q4 2025 was $131.0 million at ARS Pharmaceuticals, down from $170.0 million in the prior quarter.
  • Across five years, Equity Average topped out at $359.1 million in Q2 2021 and bottomed at -$47.1 million in Q3 2022.
  • The 5-year median for Equity Average is $219.6 million (2024), against an average of $182.9 million.
  • The largest annual shift saw Equity Average crashed 113.81% in 2022 before it soared 868.14% in 2023.
  • A 5-year view of Equity Average shows it stood at $150.4 million in 2021, then decreased by 25.97% to $111.4 million in 2022, then soared by 110.14% to $234.0 million in 2023, then dropped by 2.19% to $228.9 million in 2024, then tumbled by 42.79% to $131.0 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Equity Average are $131.0 million (Q4 2025), $170.0 million (Q3 2025), and $210.6 million (Q2 2025).